Escitalopram 10 mg tablet

Public data on escitalopram from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.

$0.0391

NADAC per ea (2026-11)

approximate acquisition cost, not a retail price

-31%

change over five years

peak $0.1596 in 2014-10

approved generic applications (ANDAs) on record for Escitalopram Oxalate

17 with a product still marketed · first 2007

Not listed

in FDA's current shortage list

no matching FDA shortage entries

NADAC per unit, monthly

ESCITALOPRAM 10 MG TABLET

Show as table

Month	NADAC per unit ($)
2013-11	0.13605
2014-02	0.13796
2014-05	0.13101
2014-08	0.13929
2014-11	0.13492
2015-02	0.13825
2015-05	0.14421
2015-08	0.13245
2015-11	0.09721
2016-02	0.10196
2016-05	0.12209
2016-08	0.12011
2016-11	0.09183
2017-02	0.08353
2017-05	0.08051
2017-08	0.07873
2017-11	0.08047
2018-02	0.07131
2018-05	0.06572
2018-08	0.07433
2018-11	0.06248
2019-02	0.06041
2019-05	0.05753
2019-08	0.06482
2019-11	0.06528
2020-02	0.05871
2020-05	0.06373
2020-08	0.06693
2020-11	0.06190
2021-02	0.06171
2021-05	0.05476
2021-08	0.05882
2021-11	0.05634
2022-02	0.04769
2022-05	0.04974
2022-08	0.05286
2022-11	0.05146
2023-02	0.04602
2023-05	0.04905
2023-08	0.04996
2023-11	0.04783
2024-02	0.04865
2024-05	0.04243
2024-08	0.04438
2024-11	0.04188
2025-02	0.04246
2025-05	0.04605
2025-08	0.04450
2025-11	0.04286
2026-02	0.04201
2026-05	0.03995
2026-08	0.03927
2026-11	0.03911

Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.

Recall records mentioning escitalopram

openFDA enforcement records, by year reported.

2016	1
2014	1

2 records since 2012. A record is one product or lot, not one recall event. Combination products that contain escitalopram are included.

What these numbers mean

NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.

Most recent recall records

Sep 28, 2016

Class IIITerminated

Escitalopram product

Reason category: Labeling or packaging error

FDA recall number D-1516-201

Jan 29, 2014

Class IITerminated

Escitalopram product

Reason category: Labeling or packaging error

FDA recall number D-839-2014

Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.

Articles that mention escitalopram

4 GxRadar articles cite or discuss this drug.

Price histories · Data story · 6 min

What pharmacies paid for six generic antidepressants, 2013 to 2026

Federal NADAC data for sertraline, escitalopram, citalopram, fluoxetine, trazodone and duloxetine show three very different price paths since 2013, and FDA approval records help explain them.

Labels & identifiers · Explainer · 6 min

Boxed warnings, FDA's most prominent label warning, explained

What 21 CFR 201.57 requires of a boxed warning, how many prescription labels carry one (about a third, by two counts 14 years apart), and why a generic's box matches the brand's.

Benchmarks & how prices are set · Data story · 7 min

The 2024 NADAC swings, and the three-month average that followed

In 2024 the federal benchmark for generic drug costs lurched up and down across nearly every drug at once. Our basket index shows the swings month by month, and what changed when CMS switched to a moving average.

Benchmarks & how prices are set · Data story · 6 min

The brand-generic gap in NADAC

In CMS's Oct. 28, 2026 cost file, brand tablets and capsules cost pharmacies a median 21 times the matching generic. For amlodipine the multiple was 857. Where the gap is widest, and where it nearly closes.